The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies

https://journals.sagepub.com/doi/10.1177/26330040231188979 The Chrysalis Task Force launched by the International Rare Diseases Research Consortium (IRDiRC) - of which EURORDIS is a member - has produced an article identifying the key financial and non-financial factors that make rare disease research and development more attractive to companies. The Task Force is comprised of thought leaders from companies, patient advocacy groups, regulatory agencies, and research funders. https://irdirc.org/